Saturday, September 22, 2012

GlobeImmune ipo stock price

GlobeImmune ipo stock price, GlobeImmune ipo release date,GlobeImmune ipo stock symbol, GlobeImmune ipo prospectus ; U.S. biopharmaceutical company GlobeImmune intends to go public on the Nasdaq Stock Exchange under the symbol “GBIM,” the proposed financing amount of $ 60 million. The company will offer its common shares at an IPO price range of $11-$13. On the basis of the assumed IPO price of $12, the median of the announced GlobeImmune IPO price range, GlobeImmune will command a market cap of $207 million. Wells Fargo Securities, and PiperJaffray are acting as the joint book-runners of GlobeImmune IPO.

 Biotechnology company GlobeImmune Inc.'s initial public offering to raise up to $75 million has been delayed, according to media reports.

GlobeImmune had scheduled an IPO for this week, according to Marketwatch, a division of the Wall Street Journal. The IPO has been rescheduled for next week, Marketwatch said, quoting an unnamed underwriting banker familiar with the offering.

Officials involved with Louisville-based GlobeImmune said earlier this week they could not talk about timing or pricing of the offering because of a "quiet period" required by the U.S. Securities and Exchange Commission, the federal regulatory body. Earlier this month, the cancer and infectious-drug company said that it planned to offer 5 million shares of stock between $11 and $13 per share, according to SEC documents related to IPOs.

GlobeImmune said in July that the company expected to use the money for future drug research and to prepare a manufacturing facility. Its stock symbol, GBIM, would be listed on the Nasdaq Global Market, the company has said.

The company's drug products for cancer and infectious diseases are based on its proprietary Tarmogen platform, according to SEC documents. Tarmogens activate a patient's immune system by stimulating a group of white blood cells - called T cells - which destroy infected or malignant cells in the body, according to the documents.

The company's lead pancreatic cancer drug is undergoing clinical trials required by the U.S. Food and Drug Administration before a drug can be marketed and sold commercially. Altogether, GlobeImmune has four Tarmogen products going through five clinical trials.

GlobeImmune is backed by venture capital companies including Morganthaler Partners LLC in Boulder and HealthCare Ventures LLC in Cambridge, Massachusetts, each of which has a 14 percent stake, according to previous SEC filings. Sequel Venture Partners LLC and Wexford Capital LP in Greenwich, Connecticut, each hold a 9 percent stake in the company. Lilly Ventures I LLC in Indianapolis and Medica Venture Partners in Herzliya, Israel, each hold a 6 percent stake. For the latest updates on the stock market, PRESS CTR + D or visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today

Related Post:

No comments:

Post a Comment